Cabotegravir and rilpivirine real-world experience
- Conditions
- People living with HIV on injectable antiretroviral treatment (CAB+RPV)Infections and Infestations
- Registration Number
- ISRCTN11668233
- Lead Sponsor
- niversity of Sussex
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 200
1. Understand the participant information and the study requirements and has the capacity to consent
2. Willing to comply with study procedures
3. Age 16 years or above
4. Is a member of one of the following groups:
4.1. LA group - PLWH who have been recently switched (within the prior 6 months) or are prospectively switched to LA CAB+RPV during the enrolment period. This includes those who have received LA CAB+RPV outside of BHIVA criteria or on compassionate grounds.
4.2. Oral ART group - PLWH who are demographically similar but not eligible for LA CAB+RPV according to BHIVA eligibility criteria and who continue oral ART within the study period (e.g. those who are HBVcoreAb+ or who have an underlying drug resistance mutation that precludes use of LA CAB+RPV). The intervention group to the oral group will be matched 3:1 by calendar period and other key variables where possible.
1. In the opinion of the investigator is unable or unwilling to comply with the study requirements
2. Aged < 16 years old
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adoption of LA CAB+RPV measured using data collected from patient medical records at the end of the study (2 years from site opening)
- Secondary Outcome Measures
Name Time Method